The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2017

Filed:

Feb. 02, 2016
Applicant:

Arena Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Bradley Teegarden, San Diego, CA (US);

Honnappa Jayakumar, San Diego, CA (US);

Hongmei Li, Warren, NJ (US);

Sonja Strah-Pleynet, Newton, MA (US);

Peter I. Dosa, San Diego, CA (US);

Assignee:

Arena Pharmaceuticals, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); C07D 231/12 (2006.01); C07D 231/16 (2006.01); C07D 405/12 (2006.01); C07D 401/12 (2006.01); A61K 31/4155 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); C07D 231/12 (2013.01); C07D 231/16 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01);
Abstract

The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HTserotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.


Find Patent Forward Citations

Loading…